Research programme: eye disorder therapeutics - Santen Pharmaceuticals/Singapore Eye Research Institute
Latest Information Update: 24 Jul 2023
Price :
$50 *
At a glance
- Originator Santen Pharmaceutical; Singapore Clinical Research Institute
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Eye disorders
Most Recent Events
- 24 Jul 2023 Discontinued - Preclinical for Eye disorders in Japan (unspecified route)
- 24 Jul 2023 Discontinued - Preclinical for Eye disorders in Singapore (unspecified route)
- 28 Dec 2018 No recent reports of development identified for preclinical development in Eye-disorders in Japan